https://www.selleckchem.com/products/bmn-673.html
Local treatment with controlled low level hyperthermia met these requisites and was especially prone to result in abscopal immune activity on its own. Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the association between body composition and clinical outcomes in ICI-treated mRCC patients. We performed a retrospective analysis of 79 ICI-treated mRCC pat
Like
Comment
Share
